PATENT CLAIM ANALYSIS

Application Number: 15985541
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-01
Patent Classification: ["514", "013300"]

Abstract:
The present invention relates to fusion polypeptide compositions comprising immunoglobulin-type-2 binding domains of Vascular Endothelial Growth Factor Receptor, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.

Claim (Index 25):
The fusion polypeptide of  claim 1 , wherein a homodimer of said fusion polypeptide exhibits high-affinity binding to VEGF.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 93.0
- Lexical Diversity: 1.28205
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12727188', '11089803', '14336812', '11998709', '14768701']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7640178356527945
- 35 USC 102 Novelty (BERT): 0.5194674662204647
- Combined Prediction Score: 0.7395627987095615
- Mean Citation Score: 287.01060199999995
- Max Citation Score: 310.06473
- Similarity Product: 223.5616097156524

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test